Biologics Help Wyeth, Schering Blunt The Pain Of Tough U.S. Market
Executive Summary
Strong sales of biologics and global diversification buttressed both Wyeth and Schering-Plough - at least partially - against a tough U.S. operating environment in the third quarter and first nine months of 2008
You may also be interested in...
Schering Plough’s Bridion Faces FDA Setback
Safety concerns render anesthesia injection “not approvable” in U.S.
Schering Looks Overseas, Under Couch To Sustain Growth As Vytorin Stumbles
Schering-Plough's strategy for reducing its elevated cholesterol worries depends on the firm capitalizing on one industry trend while bucking a few others
Big Pharma's Leap into Biologics: Bridging both Scientific and Cultural Gaps
Pharma companies are bullish about biologics, seeing them as at least a partial solution for the pipeline troubles and reimbursement challenges bedeviling the industry. The major question is how best to bring these new biologics capabilities in-house--either piecemeal through a series of smaller acquisitions and licensing deals or in one fell swoop through the acquisition of a player with soup-to-nuts capabilities. Both strategies require delicate post-merger management skills, but many feel acquiring an end-to-end player is a faster, less risky solution to filling the biologics gap. But because few end-to-end biologics players are left for acquisition, in the future it seems likely that Big Pharma will be forced to make a serial acquisition strategy work.